Eli Lilly Denies 340B Discounts to Hospitals Without Claims Data
Eli Lilly has begun denying 340B drug discounts to hospitals that have not submitted claims-level data under its reporting requirements, according to the American Hospital Association. The AHA confirmed the action in a June 18 statement, calling it "extraordinary." The move affects hospitals participating in the 340B Drug Pricing Program, which provides discounted outpatient drugs to eligible safety-net providers. This follows ongoing disputes between drug manufacturers and covered entities over data-sharing requirements that manufacturers have imposed despite regulatory uncertainty.
Medicaid managed care organizations with hospital contracts or pharmacy carve-ins may see cost-shifting if hospitals lose 340B discounts and seek higher reimbursement rates or rebate protections in their MCO agreements.
Pharmacy · Managed Care
You might also like